RGNX shows deteriorating financial position with total liabilities increasing 69.8% to $350.3M while stockholders' equity fell 60.4% to $102.7M, indicating significant balance sheet stress.
The dramatic increase in liabilities coupled with the substantial decline in stockholders' equity suggests potential financial distress or major restructuring activity that materially weakens the company's capital position. The reduction in cash reserves to $34.5M further compounds concerns about the company's ability to fund operations, particularly given the continued substantial operating losses.
RGNX's financial position deteriorated meaningfully during the period, with total liabilities growing substantially to $350.3M while stockholders' equity contracted significantly to $102.7M. While operating losses improved modestly and interest expense declined notably to $6.9M, the company continues burning cash at elevated levels with operating cash flow remaining deeply negative at -$124.0M. The combination of reduced cash reserves, expanded liabilities, and ongoing substantial losses signals heightened financial stress for this gene therapy development company.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Liabilities grew 69.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash declined 40.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Receivables grew 28.8% — monitor days sales outstanding for collection efficiency.
Operating cash flow grew 28.4% — strong conversion of earnings to cash, healthy business fundamentals.
Net income grew 14.6% — bottom-line growth signals improving overall business health.
Current liabilities rose 14.4% — increased short-term obligations, watch current ratio.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →